加拿大和意大利艰难梭菌菌株对利福霉素的不同敏感性及利福平 Etest 预测利福霉素耐药性的准确性。
Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.
机构信息
Clinical Microbiology, Jewish General Hospital, 3755 Cote Ste. Catherine Rd., Montreal, QC H3T 1E2, Canada.
出版信息
J Clin Microbiol. 2011 Dec;49(12):4319-21. doi: 10.1128/JCM.05100-11. Epub 2011 Oct 12.
Abstract
We tested the activities of rifampin (RIF) and rifaximin (RFX) against 180 Clostridium difficile clinical isolates selected from Canadian and Italian culture collections. MICs were determined by CLSI agar dilution for both drugs and by Etest for RIF. Sixteen of 85 Italian isolates (18.8%) showed high-level resistance to both rifamycins (MICs, >16 μg/ml), compared to 2 of 95 (2.1%) Canadian isolates. Two new rpoB mutations were identified in rifamycin-resistant isolates. RIF susceptibility by Etest correlated completely with susceptibility to both rifamycins determined by agar dilution.
摘要
我们测试了利福平（RIF）和利福昔明（RFX）对 180 株来自加拿大和意大利菌种库的艰难梭菌临床分离株的活性。两种药物的 MIC 均通过 CLSI 琼脂稀释法测定，RIF 的 MIC 则通过 Etest 测定。与 95 株加拿大分离株中的 2 株（2.1%）相比，85 株意大利分离株中有 16 株（18.8%）对两种利福霉素均显示高水平耐药。在耐药株中鉴定出两种新的 rpoB 突变。Etest 法检测的 RIF 敏感性与琼脂稀释法检测的两种利福霉素的敏感性完全相关。
相似文献
1
Divergent rifamycin susceptibilities of Clostridium difficile strains in Canada and Italy and predictive accuracy of rifampin Etest for rifamycin resistance.加拿大和意大利艰难梭菌菌株对利福霉素的不同敏感性及利福平 Etest 预测利福霉素耐药性的准确性。
J Clin Microbiol. 2011 Dec;49(12):4319-21. doi: 10.1128/JCM.05100-11. Epub 2011 Oct 12.
2
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.艰难梭菌临床分离株中的利福平及利福昔明耐药性
Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.
3
Rifaximin disc diffusion test for in vitro susceptibility testing of Clostridium difficile.利福昔明纸片扩散法检测艰难梭菌的体外药敏试验。
J Med Microbiol. 2011 Aug;60(Pt 8):1206-1212. doi: 10.1099/jmm.0.028571-0. Epub 2011 Feb 3.
4
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.在一家大型教学医院的一株流行艰难梭菌克隆株中发现利福平耐药的高频率。
Clin Infect Dis. 2009 Feb 15;48(4):425-9. doi: 10.1086/596315.
5
In vivo selection of rifamycin-resistant Clostridium difficile during rifaximin therapy.在利福昔明治疗期间体内筛选利福霉素耐药艰难梭菌。
Antimicrob Agents Chemother. 2012 Nov;56(11):6019-20. doi: 10.1128/AAC.00974-12. Epub 2012 Aug 20.
6
Rifamycin inhibition of WT and Rif-resistant Mycobacterium tuberculosis and Escherichia coli RNA polymerases in vitro.利福霉素对野生型和利福平耐药结核分枝杆菌和大肠杆菌 RNA 聚合酶的体外抑制作用。
Tuberculosis (Edinb). 2011 Sep;91(5):361-9. doi: 10.1016/j.tube.2011.05.002. Epub 2011 Jun 24.
7
In vitro activity and single-step mutational analysis of rifamycin SV tested against enteropathogens associated with traveler's diarrhea and Clostridium difficile.检测 rifamycin SV 对旅行者腹泻和艰难梭菌相关病原体的体外活性和单步突变分析。
Antimicrob Agents Chemother. 2011 Mar;55(3):992-6. doi: 10.1128/AAC.00688-10. Epub 2010 Dec 13.
8
Rifamycin Resistance in Clostridium difficile Is Generally Associated with a Low Fitness Burden.艰难梭菌中的利福平耐药性通常与较低的适应性负担相关。
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5604-7. doi: 10.1128/AAC.01137-16. Print 2016 Sep.
9
High-resolution melting analysis of the single nucleotide polymorphism hot-spot region in the rpoB gene as an indicator of reduced susceptibility to rifaximin in Clostridium difficile.rpoB 基因单核苷酸多态性热点区域的高分辨率熔解分析作为艰难梭菌对利福昔明敏感性降低的指标。
J Med Microbiol. 2012 Jun;61(Pt 6):780-785. doi: 10.1099/jmm.0.041087-0. Epub 2012 Feb 23.
10
Use of rifamycin drugs and development of infection by rifamycin-resistant strains of Clostridium difficile.利福霉素类药物的使用与难辨梭状芽孢杆菌利福霉素耐药株感染的发展。
Antimicrob Agents Chemother. 2013 Jun;57(6):2690-3. doi: 10.1128/AAC.00548-13. Epub 2013 Apr 1.
引用本文的文献
1
Antibiotic Resistances of Clostridioides difficile.艰难梭菌的抗生素耐药性。
Adv Exp Med Biol. 2024;1435:169-198. doi: 10.1007/978-3-031-42108-2_9.
2
The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.利福昔明-α相关的临床微生物耐药性的发展潜力：叙事性综述。
Clin Microbiol Rev. 2023 Dec 20;36(4):e0003923. doi: 10.1128/cmr.00039-23. Epub 2023 Nov 16.
3
Antimicrobial resistance in Clostridioides difficile.艰难梭菌中的抗菌药物耐药性。
Eur J Clin Microbiol Infect Dis. 2021 Dec;40(12):2459-2478. doi: 10.1007/s10096-021-04311-5. Epub 2021 Aug 24.
4
Antimicrobial resistance in Clostridioides (Clostridium) difficile derived from humans: a systematic review and meta-analysis.艰难梭菌（梭状芽孢杆菌属）源于人类的抗微生物药物耐药性：系统评价和荟萃分析。
Antimicrob Resist Infect Control. 2020 Sep 25;9(1):158. doi: 10.1186/s13756-020-00815-5.
5
Conventional and alternative treatment approaches for infection.感染的传统和替代治疗方法。
Int J Health Sci (Qassim). 2017 Jan-Mar;11(1):1-10.
6
Management of a cluster of infections among patients with osteoarticular infections.骨关节炎感染患者中聚集性感染的管理。
Antimicrob Resist Infect Control. 2017 Feb 15;6:22. doi: 10.1186/s13756-017-0181-4. eCollection 2017.
7
Toxin A-negative toxin B-positive ribotype 017 Clostridium difficile is the dominant strain type in patients with diarrhoea attending tuberculosis hospitals in Cape Town, South Africa.毒素A阴性、毒素B阳性的核糖体分型017艰难梭菌是南非开普敦结核病医院腹泻患者中的主要菌株类型。
Eur J Clin Microbiol Infect Dis. 2017 Jan;36(1):163-175. doi: 10.1007/s10096-016-2790-x. Epub 2016 Sep 30.
8
Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection.艰难梭菌感染中抗生素耐药性认识的最新进展
Ther Adv Infect Dis. 2016 Feb;3(1):23-42. doi: 10.1177/2049936115622891.
9
Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance.肠道微生物组的破坏：艰难梭菌感染和抗生素耐药性的威胁。
Genes (Basel). 2015 Dec 21;6(4):1347-60. doi: 10.3390/genes6041347.
10
Clostridium difficile infection among hospitalized HIV-infected individuals: epidemiology and risk factors: results from a case-control study (2002-2013).住院的HIV感染者艰难梭菌感染：流行病学与危险因素：一项病例对照研究（2002 - 2013年）的结果
BMC Infect Dis. 2015 Apr 22;15:194. doi: 10.1186/s12879-015-0932-x.
本文引用的文献
1
Treatment of clostridium difficile infection.艰难梭菌感染的治疗
Med Lett Drugs Ther. 2011 Feb 21;53(1358):14-5.
2
Fidaxomicin versus vancomycin for Clostridium difficile infection. fidaxomicin 与万古霉素治疗艰难梭菌感染。
N Engl J Med. 2011 Feb 3;364(5):422-31. doi: 10.1056/NEJMoa0910812.
3
Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom.艰难梭菌感染后死亡的预测因素：来自英国一所教学医院的 128 株定型病例报告。
Clin Infect Dis. 2010 Jun 15;50(12):e77-81. doi: 10.1086/653012.
4
In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospital in Houston, Texas.在德克萨斯州休斯顿一家大学医院的 359 例连续分离株中，艰难梭菌对利福昔明和利福平的体外药敏试验。
J Clin Pathol. 2010 Apr;63(4):355-8. doi: 10.1136/jcp.2009.071688.
5
Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.利福昔明：一种用于治疗肠道疾病的胃肠道选择性抗生素。
Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d.
6
High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital.在一家大型教学医院的一株流行艰难梭菌克隆株中发现利福平耐药的高频率。
Clin Infect Dis. 2009 Feb 15;48(4):425-9. doi: 10.1086/596315.
7
Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection.OPT-80在艰难梭菌感染患者2期试验中的临床疗效、安全性及药代动力学
Antimicrob Agents Chemother. 2009 Jan;53(1):223-8. doi: 10.1128/AAC.01442-07. Epub 2008 Oct 27.
8
Emergence of reduced susceptibility to metronidazole in Clostridium difficile.艰难梭菌对甲硝唑敏感性降低的出现。
J Antimicrob Chemother. 2008 Nov;62(5):1046-52. doi: 10.1093/jac/dkn313. Epub 2008 Aug 7.
9
Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.艰难梭菌临床分离株中的利福平及利福昔明耐药性
Antimicrob Agents Chemother. 2008 Aug;52(8):2813-7. doi: 10.1128/AAC.00342-08. Epub 2008 Jun 16.
10
Rifamycin antibiotics for treatment of Clostridium difficile-associated diarrhea.利福霉素类抗生素用于治疗艰难梭菌相关性腹泻。
Ann Pharmacother. 2008 Jun;42(6):827-35. doi: 10.1345/aph.1K675. Epub 2008 Apr 22.
Zotero 插件